Item 2.02. Results of Operations and Financial Condition.

On January 19, 2021, Editas Medicine, Inc. (the "Company") reported that, although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, it expects to report that it had cash, cash equivalents and marketable securities of approximately $511.8 million as of December 31, 2020. This estimated figure is preliminary and unaudited, represents a management estimate as of the date of this report and is subject to completion of the Company's financial closing procedures. The Company's independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash figure.

The information in this Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.




 Item 8.01. Other Events.

On January 19, 2021, the Company filed with the Securities and Exchange Commission (the "SEC") a preliminary prospectus supplement in connection with a proposed public offering of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"). The preliminary prospectus supplement contains an updated description of certain ongoing intellectual property matters. Accordingly, the Company is filing this information with this Current Report on Form 8-K for the purpose of supplementing and updating disclosures contained in the Company's prior filings with the SEC, including those discussed under the heading "Item 1A. Risk Factors," in the Company's most recent

Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 6, 2020 . The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits



Exhibit
No.                                        Description
  99.1       Updated Company Disclosures
104        Cover Page Interactive Data File (embedded within the Inline XBRL document)




Forward-Looking Statements

Statements in this Current Report on Form 8-K hereto about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements about the Company's estimates regarding its cash, cash equivalents and marketable securities as of December 31, 2020. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those factors discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020 and the risks described in other filings that the Company may make with the Securities and Exchange Commission. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

© Edgar Online, source Glimpses